Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Ischemic Stroke Patients over 80 Years Old: The Fukuoka Stroke Registry

被引:15
|
作者
Matsuo, Ryu [1 ,2 ]
Kamouchi, Masahiro [2 ,3 ]
Fukuda, Haruhisa [2 ,3 ]
Hata, Jun [1 ,3 ]
Wakisaka, Yoshinobu [1 ]
Kuroda, Junya [1 ]
Ago, Tetsuro [1 ]
Kitazono, Takanari [1 ,3 ]
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Med & Clin Sci, Fukuoka 812, Japan
[2] Kyushu Univ, Grad Sch Med Sci, Dept Hlth Care Adm & Management, Fukuoka 812, Japan
[3] Kyushu Univ, Grad Sch Med Sci, Ctr Cohort Studies, Fukuoka 812, Japan
来源
PLOS ONE | 2014年 / 9卷 / 10期
关键词
RT-PA; TRIAL IST-3; MANAGEMENT; GREATER-THAN-OR-EQUAL-TO-80; ALTEPLASE; TPA;
D O I
10.1371/journal.pone.0110444
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objectives: The benefit of intravenous recombinant tissue plasminogen activator (rt-PA) therapy for very old patients with acute ischemic stroke remains unclear. The aim of this study was to elucidate the efficacy and safety of intravenous rt-PA therapy for patients over 80 years old. Methods: Of 13,521 stroke patients registered in the Fukuoka Stroke Registry in Japan from June 1999 to February 2013, 953 ischemic stroke patients who were over 80 years old, hospitalized within 3 h of onset, and not treated with endovascular therapy were included in this study. Among them, 153 patients were treated with intravenous rt-PA (0.6 mg/kg). For propensity score (PS)-matched case-control analysis, 148 patients treated with rt-PA and 148 PS-matched patients without rt-PA therapy were selected by 1:1 matching with propensity for using rt-PA. Clinical outcomes were neurological improvement, good functional outcome at discharge, in-hospital mortality, and hemorrhagic complications (any intracranial hemorrhage [ICH], symptomatic ICH, and gastrointestinal bleeding). Results: In the full cohort of 953 patients, rt-PA use was associated positively with neurological improvement and good functional outcome, and negatively with in-hospital mortality after adjustment for multiple confounding factors. In PS-matched case-control analysis, patients treated with rt-PA were still at lower risk for unfavorable clinical outcomes than non-treated patients (neurological improvement, odds ratio 2.67, 95% confidence interval 1.61-4.40; good functional outcome, odds ratio 2.23, 95% confidence interval 1.16-4.29; in-hospital mortality, odds ratio 0.30, 95% confidence interval 0.13-0.65). There was no significant association between rt-PA use and risk of hemorrhagic complications in the full and PS-matched cohorts. Conclusions: Intravenous rt-PA therapy was associated with improved clinical outcomes without significant increase in risk of hemorrhagic complications in very old patients (aged. 80 years) with acute ischemic stroke.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Intravenous thrombolysis for acute cerebral ischaemia in old stroke patients ≥80 years of age
    Boulouis, Gregoire
    Dumont, Frederic
    Cordonnier, Charlotte
    Bodenant, Marie
    Leys, Didier
    Henon, Hilde
    JOURNAL OF NEUROLOGY, 2012, 259 (07) : 1461 - 1467
  • [22] Intra-arterial thrombolysis after full-dose intravenous recombinant tissue plasminogen activator for patients older than 80 years with acute ischemic stroke: What is the safety limit?
    Pieri, Alexandre
    Spitz, Mariana
    Kihara, Eduardo Noda
    Gabbai, Alberto Alain
    NEUROLOGY INDIA, 2010, 58 (03)
  • [23] Factors influencing clinical outcomes of acute ischemic stroke treated with intravenous recombinant tissue plasminogen activator
    Huang Yin-hui
    Zhuo Shi-tu
    Chen Ya-fang
    Li Ming-mei
    Lin You-yu
    Yang Mei-li
    Chen Zhen-jie
    Cai Ruo-wei
    CHINESE MEDICAL JOURNAL, 2013, 126 (24) : 4685 - 4690
  • [24] Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke
    Chapman, Sherita N.
    Mehndiratta, Prachi
    Johansen, Michelle C.
    McMurry, Timothy L.
    Johnston, Karen C.
    Southerland, Andrew M.
    VASCULAR HEALTH AND RISK MANAGEMENT, 2014, 10 : 75 - 87
  • [25] Risk Factors Associated with Outcomes of Recombinant Tissue Plasminogen Activator Therapy in Patients with Acute Ischemic Stroke
    Tseng, Yi-Ju
    Hu, Ru-Fang
    Lee, Shin-Tyng
    Lin, Yu-Li
    Hsu, Chien-Lung
    Lin, Shih-Wei
    Liou, Chia-Wei
    Lee, Jiann-Der
    Peng, Tsung-I
    Lee, Tsong-Hai
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, 17 (02)
  • [26] Intravenous Tissue Plasminogen Activator Thrombolysis in Patients With Diabetes Mellitus and Previous Stroke Response
    Rubiera, Marta
    Ribo, Marc
    STROKE, 2009, 40 (12)
  • [27] Intravenous tissue plasminogen activator for acute ischemic stroke in patients with renal dysfunction
    Wang, I-K
    Yen, T-H
    Chen, C-H
    Hsu, S-P
    Sun, Y.
    Lien, L-M
    Chang, W-L
    Lai, T-C
    Chen, P-L
    Chen, C-C
    Huang, P-H
    Lin, C-H
    Su, Y-C
    Lin, M-C
    Li, C-Y
    Sung, F-C
    Hsu, C. Y.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2021, 114 (12) : 848 - 856
  • [28] Efficacy and safety of different doses of intravenous tissue plasminogen activator in Chinese patients with ischemic stroke
    Zhou, Xiao-Yu
    Wang, Shao-Shi
    Collins, Marnie L.
    Davis, Stephen M.
    Yan, Bernard
    JOURNAL OF CLINICAL NEUROSCIENCE, 2010, 17 (08) : 988 - 992
  • [29] Efficacy and Safety of a Modified Intravenous Recombinant Tissue Plasminogen Activator Regimen in Chinese Patients with Acute Ischemic Stroke
    Pan, Shu-Ming
    Liu, Jia-Fu
    Liu, Ming
    Shen, Sa
    Li, Hao-Jun
    Dai, Li-Hua
    Chen, Xiang-Jun
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2013, 22 (05) : 690 - 693
  • [30] Experimental modeling of recombinant tissue plasminogen activator effects after ischemic stroke
    El Amki, Mohamad
    Lerouet, Dominique
    Coqueran, Berard
    Curis, Emmanuel
    Orset, Cyrille
    Vivien, Denis
    Plotkine, Michel
    Marchand-Leroux, Catherine
    Margaill, Isabelle
    EXPERIMENTAL NEUROLOGY, 2012, 238 (02) : 138 - 144